The FDA has approved a phase 1 trial for Neuralstem, a company with a patented stem cell procedure targeting ALS (Lou Gehrig’s disease) and other spinal conditions. The company’s CEO said in a press release, ”

While this trial aims to primarily establish safety and feasibility data in treating ALS patients, we also hope to be able to measure a slowing down of the ALS degenerative process.

Results are expected in 2 years. The trial will involve 12 ALS patients who will receive stem cell injections in the lumbar area of the spinal cord. Spinal Cord Resources Network, an information site for the disabled community adds hopefully: “If it makes it through all stages of testing, we will see if doctors are willing to [use] it on subjects that have injuries coming from physical injuries like diving accidents.”

Source :
ALS Association – Neuralstem Receives FDA Approval To Begin First ALS Stem Cell Trial
REUTERS – Neuralstem gets FDA OK to test stem cell drug in humans
Spinal Cord Resources Network – Neuralstem gets ok from FDA